These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

681 related items for PubMed ID: 15519006

  • 21. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
    Sever PS, Poulter NR, Dahlof B, Wedel H, ASCOT Investigators.
    J Hypertens; 2009 May; 27(5):947-54. PubMed ID: 19318984
    [Abstract] [Full Text] [Related]

  • 22. Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia.
    Jones PH, McKenney JM, Karalis DG, Downey J.
    Am Heart J; 2005 Jan; 149(1):e1. PubMed ID: 15660024
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T, Denke M, McBride P, Battisti WP, Brady WE, Palmisano J.
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
    Breuer HW.
    Curr Med Res Opin; 2001 Dec; 17(1):60-73. PubMed ID: 11464448
    [Abstract] [Full Text] [Related]

  • 27. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
    Mullins CD, Rattinger GB, Kuznik A, Koren MJ.
    Clin Ther; 2008 Dec; 30 Pt 2():2204-16. PubMed ID: 19281915
    [Abstract] [Full Text] [Related]

  • 28. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.
    Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK, TNT (Treating to New Targets) Investigators.
    J Am Coll Cardiol; 2008 Apr 15; 51(15):1448-54. PubMed ID: 18402899
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.
    Ballantyne CM, Bertolami M, Hernandez Garcia HR, Nul D, Stein EA, Theroux P, Weiss R, Cain VA, Raichlen JS.
    Am Heart J; 2006 May 15; 151(5):975.e1-9. PubMed ID: 16644314
    [Abstract] [Full Text] [Related]

  • 31. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.
    Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM, Eisenberg D, Shurzinske L, McCormick LS.
    N Engl J Med; 1999 Jul 08; 341(2):70-6. PubMed ID: 10395630
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Achievement of optimal combined lipid values in a managed care setting: is a new treatment paradigm needed?
    Sarawate CA, Cziraky MJ, Stanek EJ, Willey VJ, Corbelli JC, Charland SL.
    Clin Ther; 2007 Jan 08; 29(1):196-209. PubMed ID: 17379061
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Switching statin therapy using a pharmacist-managed therapeutic conversion program versus usual care conversion among indigent patients.
    Miller AE, Hansen LB, Saseen JJ.
    Pharmacotherapy; 2008 May 08; 28(5):553-61. PubMed ID: 18447653
    [Abstract] [Full Text] [Related]

  • 37. Effects of statin treatment in men and women with stable coronary heart disease: a subgroup analysis of the GREACE Study.
    Athyros VG, Kakafika AI, Papageorgiou AA, Paraskevas KI, Tziomalos K, Anagnostis P, Pagourelias E, Koumaras C, Karagiannis A, Mikhailidis DP.
    Curr Med Res Opin; 2008 Jun 08; 24(6):1593-9. PubMed ID: 18430270
    [Abstract] [Full Text] [Related]

  • 38. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.
    Baldassarre S, Scruel O, Deckelbaum RJ, Dupont IE, Ducobu J, Carpentier YA.
    Int J Cardiol; 2005 Oct 10; 104(3):338-45. PubMed ID: 16186066
    [Abstract] [Full Text] [Related]

  • 39. Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.
    Velussi M.
    Nutr Metab Cardiovasc Dis; 2002 Feb 10; 12(1):29-35. PubMed ID: 12125227
    [Abstract] [Full Text] [Related]

  • 40. Safety and efficacy of atorvastatin in patients with severe renal dysfunction.
    Holmberg B, Brännström M, Bucht B, Crougneau V, Dimeny E, Ekspong A, Granroth B, Gröntoft KC, Hadimeri H, Ingman B, Isaksson B, Johansson G, Lindberger K, Lundberg L, Mikaelsson L, Olausson E, Persson B, Welin D, Wikdahl AM, Stegmayr BG.
    Scand J Urol Nephrol; 2005 Feb 10; 39(6):503-10. PubMed ID: 16303728
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 35.